Improved SARS-CoV-2 sequencing surveillance allows the identification of new variants and signatures in infected patients

Abstract

Background Genomic surveillance of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the only approach to rapidly monitor and tackle emerging variants of concern (VOC) of the COVID-19 pandemic. Such scrutiny is crucial to limit the spread of VOC that might escape the immune protection conferred by vaccination strategies or previous virus exposure. It is also becoming clear now that efficient genomic surveillance would require monitoring of the host gene expression to identify prognostic biomarkers of treatment efficacy and disease progression. Here we propose an integrative workflow to both generate thousands of SARS-CoV-2 genome sequences per week and analyze host gene expression upon infection. Methods In this study we applied an integrated workflow for RNA extracted from nasal swabs to obtain in parallel the full genome of SARS-CoV-2 and transcriptome of host respiratory epithelium. The RNA extracted from each sample was reverse transcribed and the viral genome was specifically enriched through an amplicon-based approach. The very same RNA was then used for patient transcriptome analysis. Samples were collected in the Campania region, Italy, for viral genome sequencing. Patient transcriptome analysis was performed on about 700 samples divided into two cohorts of patients, depending on the viral variant detected (B.1 or delta). Results We sequenced over 20,000 viral genomes since the beginning of the pandemic, producing the highest number of sequences in Italy. We thus reconstructed the pandemic dynamics in the regional territory from March 2020 to December 2021. In addition, we have matured and applied novel proof-of-principle approaches to prioritize possible gain-of-function mutations by leveraging patients’ metadata and isolated patient-specific signatures of SARS-CoV-2 infection. This allowed us to (i) identify three new viral variants that specifically originated in the Campania region, (ii) map SARS-CoV-2 intrahost variability during long-term infections and in one case identify an increase in the number of mutations in the viral genome, and (iii) identify host gene expression signatures correlated with viral load in upper respiratory ways. Conclusion In conclusion, we have successfully generated an optimized and cost-effective strategy to monitor SARS-CoV-2 genetic variability, without the need of automation. Thus, our approach is suitable for any lab with a benchtop sequencer and a limited budget, allowing an integrated genomic surveillance on premises. Finally, we have also identified a gene expression signature defining SARS-CoV-2 infection in real-world patients’ upper respiratory ways.

Ensitrelvir is effective against SARS-CoV-2 3CL protease mutants circulating globally

“…Some COVID-19 treatment agents, especially monoclonal antibodies, lost their efficacy against SARS-CoV-2 variants because of SARS-CoV-2 S protein mutations, which restricted their clinical value [ [2] , [3] , [4] ]. COVID-19 treatment agents against novel SARS-CoV-2 variants and assessment of their efficacy are thus required [ 5 ].…”

Genomic surveillance reveals early detection and transition of Delta to Omicron Lineages of SARS-CoV-2 Variants in wastewater treatment plants of Pune, India

“…This discrepancy highlights the lack of required sequencing, i.e. at least 0.5% of the positive cases (Grimaldi et al, 2022), which impacts the ability to detect SARS-CoV-2 variants quickly and undermines the global pandemic preparedness. Our research emphasizes the effects of socioeconomic disparities, population density, and wastewater treatment as powerful strategies to stop the spread of SARS-CoV-2 (Sharifi and Khavarian-Garmsir, 2020).…”

DNA Oligonucleotides as Antivirals and Vaccine Constituents against SARS Coronaviruses: A Prospective Tool for Immune System Tuning

“…A radically new approach uses computer modelling, taking into account the avalanche of accumulated databases of SARS-CoV-2 genomic sequences from the current pandemic [ 22 , 23 , 24 ]. Sun et al (2021) designed antisense oligonucleotides using in silico tools to disrupt the interactions between SARS-CoV-2 5′-RNAs and host proteins needed to regulate the viral infection cycle [ 25 ].…”